
10 Apr 2025
Cambridge Cognition sees another contract win in Phase 3 trials
Cambridge Cognition has been selected by a major pharmaceutical company to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical trial.

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cambridge Cognition sees another contract win in Phase 3 trials
Cambridge Cognition Holdings Plc (COG:LON) | 37.0 0 0.0% | Mkt Cap: 15.5m
- Published:
10 Apr 2025 -
Author:
Paul David Richards | Lorne P. Daniel -
Pages:
4 -
Cambridge Cognition has been selected by a major pharmaceutical company to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical trial.